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We are witnessing enormous efforts to identify prognostic and predictive 
biomarkers to inform treatment decisions in malignant mesothelioma. In this 
chapter, we will review and discuss the current literature and supportive evidence 
for the progress in development and use of biomarkers in malignant mesothe-
lioma. There are currently several clinical trials evaluating treatment options in 
mesothelioma, and this will be an up-to-date review of these trials from published 
literature.
Keywords: mesothelioma, biomarkers, ASS1, BAP1, CDKN2A, mesothelin, NF-2, 
PDL-1, VEGF, WT-1
1. Epidemiology of mesothelioma
Malignant mesothelioma (MM) is an aggressive, rare cancer of pleural (80%), 
and peritoneal cells and less frequently in the pericardium and tunica vaginalis of 
the testis. MM has historically been linked to mineral fiber exposure. Asbestos is 
a collective term given to six mineral fibers including actinolite, amosite, antho-
phyllite, chrysotile, crocidolite, and tremolite [1]. Exposure to other non-asbestos 
mineral fibers including erionite and fluoro-edenite has also been linked to MM [2]. 
However, cases of MM have been found in patients who were not exposed to these 
mineral fibers. This led researchers to discover other epidemiologies of mesothe-
lioma heavily linked to genetic mutations, including tumor suppressors like BRCA1-
associated protein (BAP1) [3].
2. Biomarkers in mesothelioma
Recent research has been aimed at studying various biomarkers in malignant 
mesothelioma. Researchers hope that by identifying and studying specific bio-
markers, new therapies can be developed that better target the unique pathways of 
malignant mesothelioma pathogenesis.
2.1 Vascular endothelial growth factor
The VEGF pathway is believed to play a critical role in angiogenesis and lym-
phangiogenesis in human malignant mesothelioma tumors [4]. In one study, more 
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than 95% of malignant pleural mesothelioma (MPM) samples stained positive for 
VEGF [5]. An increase expression of VEGF was specifically observed in the epi-
thelioid histology, more than biphasic and sarcomatoid. VEGF was not felt to have 
any prognostic significance in this study [5]. In another study, VEGF was found to 
be an independent, poor prognostic factor in MPM [6]. The phase III MAPS study 
showed that the addition of bevacizumab, a humanized anti-VEGF monoclonal 
IgG1 antibody, to frontline cisplatin/pemetrexed in unresectable malignant pleural 
mesothelioma improves overall survival (18.8 vs. 16.1; hazard ratio 0.77 [0.62–0.95]; 
p = 0.0167) compared to cisplatin/pemetrexed alone regardless of tumor histology 
[7]. Analysis from the MAPS study showed that high VEGF concentrations were 
associated with worse progression free survival and overall survival but VEGF did 
not have a clinically meaningful predictive significance of response to bevacizumab 
[8]. Other antiangiogenic agents like Sorafenib and axitinib have showed limited 
activity in malignant mesotheliomas [9, 10]. Ramucirumab is a recombinant human 
immunoglobulin G1 monoclonal antibody that binds to the extracellular domain 
of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, 
and VEGF-D. A recently published Phase II abstract showed that the addition 
of Ramucirumab to gemcitabine significantly improved the overall survival in 
advanced MPM patients who progressed on first-line platinum-pemetrexed chemo-
therapy. This was observed regardless of patient age, tumor stage (locally advanced 
vs. metastatic), histotype (epithelioid vs. non-epithelioid), and time to progression 
at the first-line treatment [11].
2.2 Arginosuccinate synthetase
Certain cancer cells have a higher nutritional demand compared to normal cells. 
Arginine is an amino acid that plays an important role in biological and signaling 
pathways [12]. Arginine is either synthesized in the body or consumed in the diet. 
Normal cells synthesize arginine through the urea cycle. Research suggests that certain 
cancer cells cannot internally make arginine because they lack the urea cycle enzyme 
argininosuccinate synthetase 1 (ASS1) which ultimately makes them dependent on 
exogenous supplies of arginine, an important amino acid for cancer survival and 
growth [13]. ASS is a key enzyme that converts citrulline to arginine. This has led 
scientists to hypothesize that targeting the arginine synthesis pathway may be an 
effective therapeutic approach that targets cancer cells and spares normal cells.
Mesothelioma is one of the tumors that usually does not express ASS [14]. 
Arginine degradation is dependent on different enzymes, including an enzyme 
called arginine deiminase (ADI) that degrades arginine to citrulline. In turn, 
citrulline can be recycled back to arginine in normal cells through ASS [14]. A 
pegylated arginine deiminase (ADI-PEG 20) has been developed as an arginine 
depleting agent and is currently being tested in a randomized, double-blind, phase 
2/3 study in subjects with malignant pleural mesothelioma with low argininosuc-
cinate synthetase 1 expression to assess ADI-PEG 20 with pemetrexed and cisplatin 
(Clinicaltrials.gov ID NCT02709512).
2.3 Aurora kinase
Aurora kinase gene expression is upregulated in mesothelioma tumor tissue and 
is considered a negative prognostic factor [15–17]. The Aurora proteins are serine/
threonine kinases that function in various stages of mitosis. Aurora kinase proteins 
A/B play an important role in mitosis, monopolar spindles formation, chromo-
somal segregation cytokinesis, and polyploidy. These proteins are overexpressed in 
mesothelioma [18]. Aurora kinase inhibitors, like ZM447439, are able to inhibit cell 
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growth in all mesothelioma cell lines [18]. Alisertib (MLN8237) is a selective aurora 
kinase A inhibitor that is currently being evaluated in pretreated patients with 
unresectable MPM (Clinicaltrials.gov NCT02293005).
2.4 Wilms’ tumor protein
WT-1 is a zinc finger transcription factor protein that is responsible for 
controlling the expression of genes involved in cellular growth, differentiation, 
and/or apoptosis [19]. WT1 is a nuclear protein that is processed and highly 
overexpressed on the cell surface of MPM. Immunohistochemical (IHC) staining 
for WT1 is routinely used in establishing the diagnosis of mesothelioma. WT-1 
protein expression is detected by IHC in 78.1% of MPM and associated with 
improved overall survival and prognosis [20]. Although WT1 protein is expressed 
on the cell surface in the context of MHC molecules, which makes it a target for 
T-cell based immunotherapeutic approach [21]. A randomized phase II trial of 
adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality 
therapy for patients with WT-1 + MPM showed that a favorable safety profile with 
suggested improvement in progression-free survival and overall survival and a 
larger randomized trial is planned [22].
2.5 Mesothelin
Mesothelin is a tumor differentiation protein that is normally expressed in low 
amounts on the pleural, peritoneal, and pericardial mesothelial cells. Mesothelin 
is highly expressed in malignant mesothelioma as well as other cancers like 
pancreatic, ovarian, and lung adenocarcinoma [23–25] The differential expres-
sion of mesothelin between normal tissues and malignant cells made it an 
attractive candidate for cancer therapy. Mesothelin targeting agents including 
chimeric antigen receptor (CAR) T cells and vaccination strategies are currently 
in development for the treatment of MPM. CRS-207 is a live-attenuated strain 
of the bacterium Listeria monocytogenes that is engineered to express mesothelin. 
CRS-207 induces antitumor immune responses and increase the susceptibility of 
neoplastic cells to immune-mediated killing. A phase I study combining CRS-207 
and pemetrexed/cisplatin chemotherapy induced significant changes in the local 
tumor microenvironment and objective tumor responses in a majority of treated 
patients [26].
2.6 Programmed death-receptor ligand
PD-L1 is overexpressed in 40–50% of mesothelioma and associated with poor 
outcome. In one study, high PD-L1 expression was associated with non-epithelioid 
MM, poor clinical outcome, and increased immunological infiltrates [27]. Several 
PD-L1 and PD1 targeting agents have been studied in mesothelioma with modest 
activity. Pembrolizumab, nivolumab, and ipilimumab are routinely used in the 
second-line therapy of malignant mesothelioma. PD-L1 testing is not required for 
prescribing pembrolizumab or nivolumab in the second-line therapy for patients 
with PMP [28]. Limited data suggests that high PD-L1 expression (≥25% positive 
tumor cells) seems to be a predictor of higher overall response rate to nivolumab on 
nivolumab plus ipilimumab and even better objective response rate when the PD-L1 
expression is >50% [29]. Real-world data suggests that the high PD-L1 expression 
(≥50%) and non-epithelioid histology are associated with an improved objective 
response rate to pembrolizumab compared to intermediate (5–49%) and negative 




BRCA1-associated protein (BAP1) is a powerful deubiquitylating enzyme that 
acts to suppress the tumor growth. This means that it removes ubiquitin tags from 
specific proteins to modify and regulate their function or interaction with other 
molecules. BAP1 has been shown to have different tumor-suppressing functions 
when localized to the nucleus vs. cytoplasm. In the nucleus, it is promoted to 
double-stranded DNA break sites to aid in repair via homologous recombination, 
therefore inhibiting the growth of the damaged, mutated DNA [31, 32]. In the 
cytoplasm, BAP1 deubiquitylates type-3 inositol-1,4,5-trisphosphate-receptor 
(IP3R3) on the endoplasmic reticulum (ER). Once stabilized, IP3R3 allows the 
efflux of calcium (Ca2+) from the ER into the cytoplasm. This increase in Ca2+ pro-
motes cytochrome c activation and induces cell apoptosis [32, 33]. More recently, it 
has been proposed that BAP1 also regulates ferroptosis, an iron-dependent pro-
grammed cell death via the repression of cystine transporter SLC7A11 [34].
Somatic inactivating mutations in BAP1 have been associated with numerous 
malignancies including female reproductive cancers, uveal melanoma, renal cell 
carcinoma, pancreatic cancer, and leukemia [35–41]. Somatic mutations in BAP1 
were also initially reported in up to 23% of MPM [42]. These results were repro-
duced in various studies with BAP1 loss ranging from 20 to 60% in MM, further 
exemplifying its major role in the development of malignancy [35, 43–45].
Germline mutations in BAP1 are associated with a novel cancer syndrome 
named “BAP1 Cancer Syndrome.” This syndrome infers increased susceptibility 
to a variety of malignancies including mesothelioma, uveal and skin melanoma, 
cholangiocarcinoma, renal cell, basal cell, and squamous cell carcinomas, among 
others [32]. Malignant mesotheliomas that develop in BAP1 germline mutation 
carriers tend to be less aggressive with better prognosis and improved survival 
compared to sporadic mesothelioma [46].
There are currently no standard therapeutic approach for BAP1 loss in meso-
thelioma. Histone deacetylase (HDAC) inhibitors reversed the H2A hyperubiqui-
tination caused by BAP1 loss, and they shift the gene expression profile of class 2 
cells toward a class 1 profile in a UVM cell line [47, 48]. A phase 3 study comparing 
vorinostat (an HDAC inhibitor) with placebo in relapsed or refractory MPM 
concluded vorinostat did not improve overall survival compared to placebo and led 
to a statistically significant but not clinically relevant improvement in PFS [48, 49]. 
Molecular analysis to detect BAP1 mutations in patients treated on this study has 
not been reported [48, 49].
BAP1 loss leads to increased expression of enhancer of zeste homolog 2 (EZH2) 
protein [50]. EZH2 is a protein component of the polycomb repressive complex 2 
(PRC2) enzyme involved in chromatin modification [51]. Analysis of The Cancer 
Genome Atlas (TCGA) data revealed that EZH2 mRNA expression was increased 
in mesothelioma tumor samples [50]. Silencing EZH2 induced the apoptosis in 
BAP1-mutant mesothelioma cell lines [50]. EZH2 inhibition also reduced the 
mesothelioma tumor size in BAP1-mutant mice [50]. By contrast, Schoumacher 
and colleagues showed that EZH2 was not overexpressed in UM cases, and sub-
sequently, UM cases with BAP1 loss were insensitive to the EZH2 inhibitor, EPZ-
6438 [52]. These findings highlight the tissue-dependent expression of epigenetic 
regulators and differing roles in carcinogenesis. Tazemetostat (an EZH2 inhibitor) 
has been tested in mesothelioma patients with BAP1 loss-of-function and showed 
some promising activity. The disease control of tazemetostat was 47% at 12 weeks 
and 25% of patients-maintained disease control at 24 weeks [53].
PARP inhibition is another potential targeted therapy option in patients 
with somatic or germline BAP1 mutations. Clinical trials are underway to 
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investigate the role of PARP inhibitors in patients with DNA-repair protein 
defects, including BAP1. Currently there is a trial investigating niraparib (PARP 
inhibitor) (Clinicaltrials.gov ID NCT03207347) and three trials investigating 
olaparib (another PARP inhibitor) in BAP1 and other DDR deficient neoplasms 
(Clinicaltrials.gov ID NCT03786796, NCT03531840, NCT03375307). Combination 
therapies using nivolumab in combination with talazoparib in unresectable or meta-
static melanoma patients with mutations in BRCA or BRCAness are also underway 
(NCT03531840).
A recent study published by Hassan et al. suggested that patients with pleural 
mesothelioma with loss-of-function mutations in BAP1 and other DNA repair genes 
appeared to benefit from platinum chemotherapy compared with patients without 
inherited mutations [54].
2.8 Neurofibromatosis type 2
Neurofibromatosis type 2 (NF2) is another tumor suppressor gene most commonly 
associated with the disorder Neurofibromatosis 2, in which malignancies including 
vestibular schwannomas and meningiomas are common. However, in more recent years, 
the somatic mutations of NF2 have been linked to malignant mesothelioma, in addition 
to multiple other organ systems [55–57]. NF2 gene is somatically mutated in 40–50% of 
MPM [57–59]. NF2 encodes for a multifunctional protein named merlin which regulates 
the hippo signaling pathway among other pathways related to tumor progression and 
oncogenic activity [56, 60]. Disruption of the NF2 tumor suppressor gene by muta-
tion and/or deletion results in lack of expression of the functional merlin protein [61]. 
Merlin is a protein that regulates cellular cytoskeleton dynamic through its function as 
a linker between membrane proteins and the actin cytoskeleton. Merlin is involved in 
cell communication, adhesion, and motility, which are functions that are related to the 
invasive properties of malignant cells [62]. Merlin exerts its effect through forming a 
complex with the cytoplasmic kinase protein focal adhesion kinase (FAK) controlling 
cell adhesion, migration, and invasion through integrating signals from growth factor 
receptors and integrins [63–65]. Merlin inactivation is a critical step in MM pathogenesis 
and is related, at least in part, to upregulation of FAK activity. Merlin attenuates FAK 
phosphorylation and disrupt the interaction of FAK with its binding partners Src and 
p85, the regulatory subunit of Pi3K [58]. FAK expression and/or activity are reported to 
be upregulated in a wide range of malignancies including mesothelioma [62].
Loss of merlin, a product of the neurofibromatosis 2 tumor suppressor gene 
is being evaluated as a biomarker for FAK inhibitor sensitivity in mesothelioma. 
When NF2 is absent or inactivated, these regulation pathways are disrupted which 
result in the constitutive activation of oncogenesis [56]. Interestingly, when NF2 
is reactivated and expressed in mesothelioma cells, invasiveness regresses [62]. 
Targeting NF2 or downstream proteins like FAK has become an attractive thera-
peutic strategy in mesothelioma. Defactinib (VS-6063) is a FAK inhibitor. Merlin-
low mesothelioma cell lines are more sensitive to defactinib than merlin-high cell 
lines in vitro and in vivo [62].
Defactinib (VS-6063) has been evaluated as a single agent in MPM. The phase 
II COMMAND trial was a randomized, placebo-controlled phase II study of 
defactinib in patients with unresectable mesothelioma who had had a stable disease 
or a PR following at least 4 cycles of platinum-based pemetrexed. Patients were 
randomized to receive maintenance defactinib or placebo. Patients were stratified 
by tumor merlin immunohistochemistry status (high vs. low) prior to randomiza-
tion, and the study aimed to measure the effect of treatment allocation on the 
overall survival and progression-free survival. The study showed no difference in 
the progression-free survival or overall survival between the two treatment arms 
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in the intent-to-treat population or in patients who had merlin-low tumors [66]. 
Defactinib is currently being evaluated in combination with pembrolizumab in 
patients with pleural mesothelioma (Clinicaltrials.gov NCT04201145).
Another therapeutic approach that is currently being evaluated in NF2 mutant 
MM is NEDD8 activating enzyme (NAE) inhibition. Merlin is a negative regulator 
of mTORC1 and the loss of Merlin results in constitutive activation of the mTORC 
pathway [67, 68]. The exact mechanism by which Merlin suppresses mTOR signaling 
is unknown.
Merlin also suppresses tumorigenesis by accumulating in the nucleus and 
binding to the cullin E3 ubiquitin ligase CRL4(DCAF1) which suppresses its 
ubiquitination activity [69]. Merlin loss drives tumorigenesis by activating the E3 
ubiquitin ligase CRL4(DCAF1), thereby inhibiting the Hippo pathway component 
Lats [70]. MLN4924, a NEDD8 activating enzyme (NAE) inhibitor that sup-
presses CRL4(DCAF1), attenuates the activation of YAP in NF2-mutant tumor 
cells [70]. A phase I/II clinical trial is investigating MLN4924 (Pevonedistat) alone 
and in combination with chemotherapy in patients with mesothelioma. MLN4924 
(Pevonedistat) is a NAE inhibitor that suppresses CRL4DCAF1 and attenuates the 
activation of YAP in NF2-mutant tumor cells.
2.9 Cyclin-dependent kinase inhibitor 2A (CDKN2A)
Cyclin-dependent kinase inhibitor 2A is a tumor suppressor gene that is 
commonly mutated in MM. It encodes both proteins INK4A and ARF [71]. INK4A 
inhibits critical cell cycle regulators cyclin-dependent kinase 4 (CDK4) and 
cyclin-dependent kinase 6 (CDK6) [72]. These two kinases function to activate 
retinoblastoma protein (RB) and allow for cell cycle progression [72]. Without 
INK4A, cell cycle progression remains unchecked and allows for continuation and 
possible proliferation of damaged DNA. ARF acts by promoting MDM2 degrada-
tion; this degradation is necessary for the activation of p53, a widely studied 
tumor suppressor [73]. With p53 activated, the cell cycle is arrested and growth is 
suppressed. Without ARF, p53 activation is limited and cell cycle progression can 
continue unchecked.
Mutations in CDKN2A have been shown to be induced by environmental toxins 
like asbestos [74]. Furthermore, the loss of CDKN2A in MM is associated with 
worse prognosis and decreased survival [15, 75].
3. Multi-biomarker-driven clinical trials
The Mesothelioma Stratified Therapy Trial (MiST) is a large multi-drug phase 
II clinical trial evaluating the use of different biomarkers for the treatment selec-
tion in relapsed mesothelioma. BRCA1/BAP1-mutated mesothelioma treatment 
is being studied with Rucarapib, a PARP inhibitor. PARP enzymes are critical for 
cell function; they aid in DNA transcription, repair, and cell cycle regulation [76]. 
It is believed that by inhibiting these critical enzymes, damage will accumulate 
within the cell and apoptosis will be induced. In patients with absent INK4A genes, 
apamaciclib is being studied. Apamaciclib is a selective CDK4/6 inhibitor, theoreti-
cally working to “replace” the function of INK4A in these mutated cells to stop the 
cell cycle progression and tumor growth [77]. Patients with PDL1 positive mesothe-
lioma are being treated with Atezolizumab and Bevacizumab. Atezolizumab is an 
anti-PDL1 antibody that selectively binds to PDL1 and prevents its interaction with 
B7.1 on the antigen-presenting cell (APC). This inhibits the cancer cell from utilizing 
PDL1 to evade the immune system [78, 79]. Lastly, for patients with no biomarkers, 
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pembrolizumab and bemcentinib are being studied. Pembrolizumab is a monoclonal 
antibody against PD-1 and functions by binding PD-1 receptor on T-cells, inhibiting 
their binding with PDL1 [80, 81]. Bemcentinib is an AXL receptor tyrosine kinase 
inhibitor, a regulator of various critical cell functions including proliferation and 
motility, among others [82].
4. Conclusions
Over the last two decades, we have witnessed enormous efforts to identify 
prognostic and predictive biomarkers to inform treatment decisions in malignant 
mesothelioma. The medical and scientific community continue to search for optimal 
biomarkers to advance the field of precision medicine. Advances in molecular 
and diagnostic testing have not changed the current landscape of mesothelioma 
treatment. More biomarker-driven clinical trials are underway. The rarity of the 
disease makes it difficult to move these advances at a faster pace. Different pathways 
continue to be under investigation. These include: BAP1, NF2, CDKN2A, PD-L1, 
VEGF, WT-1, mesothelin, ASS, and aurora kinases. Biomarker-driven clinical trials, 
access to real-world data, and collaborative efforts should continue to move the field 
forward and help finding clinically actionable biomarkers.
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